S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

OTCMKTS:DCTHDelcath Systems Stock Price, Forecast & News

$12.43
+0.03 (+0.24 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.69
Now: $12.43
$12.77
50-Day Range
$8.02
MA: $10.71
$12.84
52-Week Range
$5.15
Now: $12.43
$95.90
Volume81,615 shs
Average Volume49,177 shs
Market Capitalization$48.40 million
P/E RatioN/A
Dividend YieldN/A
Beta0.45
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.20 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:DCTH
CUSIPN/A
Phone212-489-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.58 million
Book Value($94.88) per share

Profitability

Net Income$-8,880,000.00
Net Margins-561.96%

Miscellaneous

Employees46
Market Cap$48.40 million
Next Earnings DateN/A
OptionableNot Optionable
$12.43
+0.03 (+0.24 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DCTH News and Ratings via Email

Sign-up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Delcath Systems (OTCMKTS:DCTH) Frequently Asked Questions

How has Delcath Systems' stock price been impacted by COVID-19?

Delcath Systems' stock was trading at $9.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DCTH stock has increased by 35.1% and is now trading at $12.43.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Delcath Systems?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Delcath Systems
.

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (OTCMKTS:DCTH) released its quarterly earnings results on Thursday, August, 13th. The company reported ($1.90) earnings per share for the quarter, missing the consensus estimate of ($1.69) by $0.21.
View Delcath Systems' earnings history
.

When did Delcath Systems' stock split? How did Delcath Systems' stock split work?

Delcath Systems's stock reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of Delcath Systems stock prior to the reverse split would have 1 shares after the split.

What price target have analysts set for DCTH?

2 brokers have issued 1-year price objectives for Delcath Systems' stock. Their forecasts range from $19.00 to $20.00. On average, they expect Delcath Systems' share price to reach $19.50 in the next twelve months. This suggests a possible upside of 56.9% from the stock's current price.
View analysts' price targets for Delcath Systems
.

Has Delcath Systems been receiving favorable news coverage?

News stories about DCTH stock have trended somewhat negative on Friday, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Delcath Systems earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Delcath Systems
.

Are investors shorting Delcath Systems?

Delcath Systems saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 1,200 shares, an increase of 20.0% from the April 15th total of 1,000 shares. Based on an average daily trading volume, of 200 shares, the days-to-cover ratio is currently 6.0 days.
View Delcath Systems' Short Interest
.

Who are some of Delcath Systems' key competitors?

What other stocks do shareholders of Delcath Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Delcath Systems investors own include Amarin (AMRN), Nabriva Therapeutics (NBRV), Aduro BioTech (ADRO), Anavex Life Sciences (AVXL), Crispr Therapeutics (CRSP), Novavax (NVAX), Occidental Petroleum (OXY), ABIOMED (ABMD), Agile Therapeutics (AGRX) and Altimmune (ALT).

Who are Delcath Systems' key executives?

Delcath Systems' management team includes the following people:
  • Dr. Jennifer K. Simpson, Pres, CEO & Director (Age 51)
  • Ms. Barbra C. Keck M.B.A., MBA, CFO & Sec. (Age 41)
  • Mr. John Purpura, Exec. VP & Global Head of Operations (Age 58)
  • Mr. Thomas Johnson, Sr. Director of Corp. Communications
  • Mr. Robin Wagge, Sr. VP of Rubenstein Associates

What is Delcath Systems' stock symbol?

Delcath Systems trades on the OTCMKTS under the ticker symbol "DCTH."

Who are Delcath Systems' major shareholders?

Delcath Systems' stock is owned by a number of institutional and retail investors. Top institutional investors include Ikarian Capital LLC (2.41%), Hudson Bay Capital Management LP (2.28%) and Worth Venture Partners LLC (0.65%). Company insiders that own Delcath Systems stock include Barbra Keck, John Purpura and William Dodge Rueckert.
View institutional ownership trends for Delcath Systems
.

Which major investors are buying Delcath Systems stock?

DCTH stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Hudson Bay Capital Management LP, and Worth Venture Partners LLC. Company insiders that have bought Delcath Systems stock in the last two years include Barbra Keck, John Purpura, and William Dodge Rueckert.
View insider buying and selling activity for Delcath Systems
.

How do I buy shares of Delcath Systems?

Shares of DCTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Delcath Systems' stock price today?

One share of DCTH stock can currently be purchased for approximately $12.43.

How big of a company is Delcath Systems?

Delcath Systems has a market capitalization of $48.40 million and generates $1.58 million in revenue each year. Delcath Systems employs 46 workers across the globe.

What is Delcath Systems' official website?

The official website for Delcath Systems is www.delcath.com.

How can I contact Delcath Systems?

Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The company can be reached via phone at 212-489-2100 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.